E&Y: A resilient biotech industry registers its first profitable year

Ernst & Young has scanned the global biotech industry and found that established biotech hubs not only weathered 2009's scary economic downturn, they achieved a collective profitability for the very first time. But the big accounting firm wasn't ready to call for the champagne just yet. The yawning gap between the industry's haves versus the have-nots is just as big as ever, small fish in the drug development pond face plenty of challenges obtaining operating cash and anyone trying to make...